Uk Based Huma Expands US Presence With Aluna Acquisition

This partnership will help Huma expand its M&A strategy, targeting companies that strengthen its digital health ecosystem.

Aluna is a US-based startup that focuses on AI-powered remote monitoring for respiratory diseases like asthma and COPD.

Its platform uses FDA-approved spirometry devices, a mobile app, and a provider portal to help doctors monitor lung function and patient adherence in real time.

Read More - Dutch Medtech Company Hy2Care Secures €4.5Mn To Launch Clinical Trial

These steps will help Huma strengthen its product offerings and global presence. The news comes as healthcare systems around the world increasingly adopt remote patient monitoring and AI-driven clinical tools, driven by post-pandemic changes and growing demand for decentralized care.

“Today’s announcements mark a new chapter for Huma as we strive to build the most impactful healthcare company in the world,” said Dan Vahdat, Founder and CEO of Huma. “By integrating Aluna’s leading respiratory monitoring solutions into our platform and working to secure growth capital for further acquisitions, we are creating a complete ecosystem to deliver even greater value to health systems, life sciences, and - most importantly - patients around the world.”

By adding Aluna’s technology to the Huma Cloud Platform, Huma will strengthen its chronic respiratory care services across more than 150 U.S. health systems, covering over 500,000 patients.

This move boosts Huma’s presence in the U.S., where over 40 million people live with asthma or COPD.

“Joining forces with Huma offers a remarkable opportunity to amplify our impact and extend the reach of our AI-driven respiratory management platform to a wider patient base worldwide,” said Charvi Shetty, CEO of Aluna. “We are excited about the prospect of integrating our technology into the Huma Cloud Platform, creating a truly holistic digital health solution that empowers both patients and healthcare professionals in the effective management of respiratory conditions.”

Huma will relaunch Aluna’s technology on its platform with an upgraded FDA Class II status, allowing it to be used more widely in clinical settings.

At the same time, Huma has announced a new partnership with Eckuity Capital, a healthcare investment firm based in New York and London.

“We help Huma acquire companies that, on their own, may not fully realize their potential—but when integrated into Huma’s cloud platform, become highly complementary and transformative,” said Youssef Sebban, Managing Partner at Eckuity Capital. “This synergy not only amplifies their impact on the healthcare ecosystem but also drives outsized value creation for investors and shareholders.”

“We believe Dan and Huma’s leadership team brings the much-needed bold vision to develop one of the most meaningful healthcare companies of the 21st century,” added Vishal Jain, Managing Partner at Eckuity Capital. “The AI-led transformation of care that we will witness over the next two decades needs a reliable, real-time, and responsive infrastructure that very few companies can offer globally, and Huma is one of the most capable companies that can deliver on this promise.”

About Huma

Huma, founded in London in 2011 (originally known as Medopad), has grown into a global healthtech company operating across four continents. As a digital-first health unicorn, Huma uses its platform to support patients, healthcare providers, and researchers.